The Indian pharmaceutical market recorded a 7.9% growth in July 2025, driven by strong volume performance in cardiac and anti-diabetes therapies, according to a report by market research firm Pharmarack. These two segments, which together contribute nearly 25% of the domestic market’s monthly sales value, posted value growth of 14.1% and 9% respectively.
Other therapeutic categories also showed robust performance. Urology and antineoplastics, each accounting for around 2% of monthly sales, registered double-digit value growth. The respiratory segment followed closely with a 9.2% increase in value.
Sheetal Sapale, vice-president (commercial) at Pharmarack, attributed the overall market expansion to new product introductions and price growth across most therapies. She noted that among the top therapies, cardiac and anti-infectives demonstrated strong volume growth, while new launches significantly boosted the anti-diabetes segment.
The report highlighted continued momentum in the GLP-1 agonists market, with Semaglutide and Tirzepatide driving growth. Semaglutide is marketed under brands such as Rybelsus (oral) and Wegovy (injectable), while Tirzepatide is sold as Mounjaro. Both injectables are used for managing type 2 diabetes and aiding weight loss.
Sapale observed that aggressive promotion of newly launched brands contributed to the surge in July. Although Tirzepatide’s entry had initially impacted Semaglutide’s performance, Wegovy has helped restore strong sales momentum for the molecule.
The report also emphasized strategic growth areas in the Indian pharma industry, particularly biologics and biosimilars. These segments are reshaping the market landscape, with biosimilars currently representing a Rs 3.9 billion market and growing at a five-year compound annual growth rate of 15%.
Sapale stated that biologics and biosimilars are becoming increasingly vital due to evolving disease patterns and associated complications, positioning them as key drivers of future growth in the Indian pharmaceutical sector.
